Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04923893 · ClinicalTrials.gov registry record · Phase 3
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
A Phase 3 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 743
- Enrollment target
- 20
- Study locations
NCT04923893 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 743 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (36% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT04923893, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 743 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Cilta-cel
- DRUG Bortezomib
Study Locations (20)
New York
- Columbia University Medical Center - New York
- Memorial Sloan-Kettering Cancer Center - New York
- New York Presbyterian-Weill Cornell Medical College - New York
Florida
- University of Miami Health System - Miami
- AdventHealth Cancer Institute - Orlando
Kentucky
- University of Kentucky - Lexington
- Norton Cancer Institute - Louisville
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
- Henry Ford Cancer Institute - Detroit
Pennsylvania
- Thomas Jefferson University - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
California
- UCSF - San Francisco
Connecticut
- Yale Cancer Center - New Haven
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 743 participants |
| Start Date | 2021-08-19 |
| Est. Completion | 2036-09-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04923893
The ClinicalTrials.gov registry entry for NCT04923893 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 743 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (36% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04923893 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04923893 about?
NCT04923893 is a clinical study titled "A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy". The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple...
What is the current status of trial NCT04923893?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 743 participants. The study started on 2021-08-19. Estimated completion is 2036-09-22.
What conditions does trial NCT04923893 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04923893?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG), Cilta-cel (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT04923893?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04923893 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.